Edition:
United States

Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

0.22USD
12:56pm EST
Change (% chg)

$0.00 (+0.86%)
Prev Close
$0.22
Open
$0.22
Day's High
$0.23
Day's Low
$0.22
Volume
37,020
Avg. Vol
109,540
52-wk High
$1.37
52-wk Low
$0.19

Chart for

About

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize,... (more)

Overall

Beta: 3.01
Market Cap(Mil.): $24.96
Shares Outstanding(Mil.): 113.39
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Bio-Path Holdings Q3 loss per share $0.02

* Bio-Path Holdings reports third quarter 2017 financial results

Nov 09 2017

BRIEF-Bio-Path Holdings announces $4 mln registered direct offering

* Bio-Path Holdings, Inc. Announces $4 million registered direct offering

Nov 03 2017

BRIEF-Bio Path Holdings receives notice of allowance for key U.S. composition of matter patent

* Bio Path Holdings - U.S. PTO has issued notice of allowance for claims related to co's liposomal delivery and antisense technology, dnabilize Source text for Eikon: Further company coverage:

Jul 19 2017

BRIEF-Bio-Path Holdings appoints Mark Colonnese to its board

* Bio-Path Holdings appoints Mark Colonnese to its board of directors Source text for Eikon: Further company coverage:

Jul 17 2017

Competitors

Earnings vs. Estimates